(MRK) Merck - Ratings and Ratios
Exchange: NYSE •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US58933Y1055
Oncology Vaccines Antimicrobials Diabetes Cardiovascular
Dividends
| Dividend Yield | 3.25% |
| Yield on Cost 5y | 4.82% |
| Yield CAGR 5y | 5.91% |
| Payout Consistency | 93.7% |
| Payout Ratio | 37.9% |
| Risk via 10d forecast | |
|---|---|
| Volatility | 28.5% |
| Value at Risk 5%th | 42.7% |
| Relative Tail Risk | -8.86% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.08 |
| Alpha | -6.67 |
| CAGR/Max DD | 0.00 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.449 |
| Beta | 0.373 |
| Beta Downside | 0.452 |
| Drawdowns 3y | |
|---|---|
| Max DD | 43.44% |
| Mean DD | 15.80% |
| Median DD | 11.03% |
Description: MRK Merck December 01, 2025
Merck & Co. (NYSE: MRK) is a global, diversified healthcare firm that markets prescription medicines (e.g., Keytruda, Januvia/Janumet, Gardasil), veterinary pharmaceuticals, and animal-health vaccines, while also maintaining a pipeline of oncology collaborations (Daiichi Sankyo ADCs, AstraZeneca Lynparza, LaNova LM-299) and partnership agreements with firms such as Eisai, Bayer and Moderna.
Key performance indicators from the most recent fiscal year show total revenue of roughly $13.5 billion, with Keytruda contributing about $5.5 billion (≈ 41 % of sales) and an R&D spend of $5.6 billion (≈ 41 % of revenue). The company’s dividend yield sits near 3 % and its cash-flow conversion remains above 80 %, while the broader pharma sector benefits from an aging global population and accelerating adoption of immuno-oncology therapies-both of which support Merck’s growth outlook.
For a deeper quantitative assessment, you may find ValueRay’s analyst tools useful.
Piotroski VR‑10 (Strict, 0-10) 5.5
| Net Income (19.03b TTM) > 0 and > 6% of Revenue (6% = 3.85b TTM) |
| FCFTA 0.10 (>2.0%) and ΔFCFTA -2.55pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 29.47% (prev 17.06%; Δ 12.41pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.13 (>3.0%) and CFO 17.07b <= Net Income 19.03b (YES >=105%, WARN >=100%) |
| Net Debt (23.20b) to EBITDA (27.57b) ratio: 0.84 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.66 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (2.50b) change vs 12m ago -1.69% (target <= -2.0% for YES) |
| Gross Margin 78.32% (prev 75.82%; Δ 2.50pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 52.00% (prev 53.75%; Δ -1.75pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 19.43 (EBITDA TTM 27.57b / Interest Expense TTM 1.18b) >= 6 (WARN >= 3) |
Altman Z'' 4.96
| (A) 0.15 = (Total Current Assets 47.56b - Total Current Liabilities 28.63b) / Total Assets 129.55b |
| (B) 0.56 = Retained Earnings (Balance) 72.23b / Total Assets 129.55b |
| (C) 0.19 = EBIT TTM 23.00b / Avg Total Assets 123.54b |
| (D) 0.89 = Book Value of Equity 68.82b / Total Liabilities 77.64b |
| Total Rating: 4.96 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 82.99
| 1. Piotroski 5.50pt |
| 2. FCF Yield 4.59% |
| 3. FCF Margin 20.31% |
| 4. Debt/Equity 0.80 |
| 5. Debt/Ebitda 0.84 |
| 6. ROIC - WACC (= 16.48)% |
| 7. RoE 38.95% |
| 8. Rev. Trend 70.32% |
| 9. EPS Trend 13.51% |
What is the price of MRK shares?
As of December 06, 2025, the stock is trading at USD 99.72 with a total of 16,430,388 shares traded.
Over the past week, the price has changed by -4.87%, over one month by +18.17%, over three months by +18.88% and over the past year by -0.13%.
Over the past week, the price has changed by -4.87%, over one month by +18.17%, over three months by +18.88% and over the past year by -0.13%.
Is MRK a buy, sell or hold?
Merck has received a consensus analysts rating of 4.04.
Therefore, it is recommended to buy MRK.
- Strong Buy: 12
- Buy: 3
- Hold: 11
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the MRK price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 104.3 | 4.6% |
| Analysts Target Price | 104.3 | 4.6% |
| ValueRay Target Price | 103.2 | 3.5% |
MRK Fundamental Data Overview November 29, 2025
Market Cap USD = 261.34b (261.34b USD * 1.0 USD.USD)
P/E Trailing = 13.8399
P/E Forward = 11.1359
P/S = 4.0685
P/B = 5.0086
P/EG = 1.1021
Beta = 0.319
Revenue TTM = 64.23b USD
EBIT TTM = 23.00b USD
EBITDA TTM = 27.57b USD
Long Term Debt = 39.97b USD (from longTermDebt, last quarter)
Short Term Debt = 1.41b USD (from shortTermDebt, last quarter)
Debt = 41.37b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 23.20b USD (from netDebt column, last quarter)
Enterprise Value = 284.50b USD (261.34b + Debt 41.37b - CCE 18.21b)
Interest Coverage Ratio = 19.43 (Ebit TTM 23.00b / Interest Expense TTM 1.18b)
FCF Yield = 4.59% (FCF TTM 13.05b / Enterprise Value 284.50b)
FCF Margin = 20.31% (FCF TTM 13.05b / Revenue TTM 64.23b)
Net Margin = 29.63% (Net Income TTM 19.03b / Revenue TTM 64.23b)
Gross Margin = 78.32% ((Revenue TTM 64.23b - Cost of Revenue TTM 13.93b) / Revenue TTM)
Gross Margin QoQ = 81.92% (prev 77.50%)
Tobins Q-Ratio = 2.20 (Enterprise Value 284.50b / Total Assets 129.55b)
Interest Expense / Debt = 0.58% (Interest Expense 238.0m / Debt 41.37b)
Taxrate = 14.20% (958.0m / 6.75b)
NOPAT = 19.73b (EBIT 23.00b * (1 - 14.20%))
Current Ratio = 1.66 (Total Current Assets 47.56b / Total Current Liabilities 28.63b)
Debt / Equity = 0.80 (Debt 41.37b / totalStockholderEquity, last quarter 51.85b)
Debt / EBITDA = 0.84 (Net Debt 23.20b / EBITDA 27.57b)
Debt / FCF = 1.78 (Net Debt 23.20b / FCF TTM 13.05b)
Total Stockholder Equity = 48.87b (last 4 quarters mean from totalStockholderEquity)
RoA = 14.69% (Net Income 19.03b / Total Assets 129.55b)
RoE = 38.95% (Net Income TTM 19.03b / Total Stockholder Equity 48.87b)
RoCE = 25.89% (EBIT 23.00b / Capital Employed (Equity 48.87b + L.T.Debt 39.97b))
RoIC = 22.93% (NOPAT 19.73b / Invested Capital 86.06b)
WACC = 6.45% (E(261.34b)/V(302.72b) * Re(7.39%) + D(41.37b)/V(302.72b) * Rd(0.58%) * (1-Tc(0.14)))
Discount Rate = 7.39% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: -100.0 | Cagr: -1.11%
[DCF Debug] Terminal Value 78.94% ; FCFE base≈13.77b ; Y1≈14.41b ; Y5≈16.75b
Fair Price DCF = 118.4 (DCF Value 293.77b / Shares Outstanding 2.48b; 5y FCF grow 5.00% → 3.0% )
EPS Correlation: 13.51 | EPS CAGR: 10.08% | SUE: 3.25 | # QB: 3
Revenue Correlation: 70.32 | Revenue CAGR: 6.75% | SUE: 0.60 | # QB: 0
EPS next Quarter (2026-03-31): EPS=1.65 | Chg30d=-0.618 | Revisions Net=-3 | Analysts=7
EPS next Year (2026-12-31): EPS=8.80 | Chg30d=-0.660 | Revisions Net=-8 | Growth EPS=-1.9% | Growth Revenue=+5.4%
P/E Trailing = 13.8399
P/E Forward = 11.1359
P/S = 4.0685
P/B = 5.0086
P/EG = 1.1021
Beta = 0.319
Revenue TTM = 64.23b USD
EBIT TTM = 23.00b USD
EBITDA TTM = 27.57b USD
Long Term Debt = 39.97b USD (from longTermDebt, last quarter)
Short Term Debt = 1.41b USD (from shortTermDebt, last quarter)
Debt = 41.37b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 23.20b USD (from netDebt column, last quarter)
Enterprise Value = 284.50b USD (261.34b + Debt 41.37b - CCE 18.21b)
Interest Coverage Ratio = 19.43 (Ebit TTM 23.00b / Interest Expense TTM 1.18b)
FCF Yield = 4.59% (FCF TTM 13.05b / Enterprise Value 284.50b)
FCF Margin = 20.31% (FCF TTM 13.05b / Revenue TTM 64.23b)
Net Margin = 29.63% (Net Income TTM 19.03b / Revenue TTM 64.23b)
Gross Margin = 78.32% ((Revenue TTM 64.23b - Cost of Revenue TTM 13.93b) / Revenue TTM)
Gross Margin QoQ = 81.92% (prev 77.50%)
Tobins Q-Ratio = 2.20 (Enterprise Value 284.50b / Total Assets 129.55b)
Interest Expense / Debt = 0.58% (Interest Expense 238.0m / Debt 41.37b)
Taxrate = 14.20% (958.0m / 6.75b)
NOPAT = 19.73b (EBIT 23.00b * (1 - 14.20%))
Current Ratio = 1.66 (Total Current Assets 47.56b / Total Current Liabilities 28.63b)
Debt / Equity = 0.80 (Debt 41.37b / totalStockholderEquity, last quarter 51.85b)
Debt / EBITDA = 0.84 (Net Debt 23.20b / EBITDA 27.57b)
Debt / FCF = 1.78 (Net Debt 23.20b / FCF TTM 13.05b)
Total Stockholder Equity = 48.87b (last 4 quarters mean from totalStockholderEquity)
RoA = 14.69% (Net Income 19.03b / Total Assets 129.55b)
RoE = 38.95% (Net Income TTM 19.03b / Total Stockholder Equity 48.87b)
RoCE = 25.89% (EBIT 23.00b / Capital Employed (Equity 48.87b + L.T.Debt 39.97b))
RoIC = 22.93% (NOPAT 19.73b / Invested Capital 86.06b)
WACC = 6.45% (E(261.34b)/V(302.72b) * Re(7.39%) + D(41.37b)/V(302.72b) * Rd(0.58%) * (1-Tc(0.14)))
Discount Rate = 7.39% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: -100.0 | Cagr: -1.11%
[DCF Debug] Terminal Value 78.94% ; FCFE base≈13.77b ; Y1≈14.41b ; Y5≈16.75b
Fair Price DCF = 118.4 (DCF Value 293.77b / Shares Outstanding 2.48b; 5y FCF grow 5.00% → 3.0% )
EPS Correlation: 13.51 | EPS CAGR: 10.08% | SUE: 3.25 | # QB: 3
Revenue Correlation: 70.32 | Revenue CAGR: 6.75% | SUE: 0.60 | # QB: 0
EPS next Quarter (2026-03-31): EPS=1.65 | Chg30d=-0.618 | Revisions Net=-3 | Analysts=7
EPS next Year (2026-12-31): EPS=8.80 | Chg30d=-0.660 | Revisions Net=-8 | Growth EPS=-1.9% | Growth Revenue=+5.4%
Additional Sources for MRK Stock
News:
Wall Street Journal |
Benzinga |
Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle